BSE Live
Mar 11, 16:01Prev. Close
222.75
Open Price
225.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 11, 15:59Prev. Close
223.02
Open Price
223.54
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
216.26 (1800)
| Cash Flow of Bliss GVS Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 94.17 | 111.34 | 115.69 | 123.66 | 91.19 | |
| Net CashFlow From Operating Activities | 97.21 | 125.92 | 43.81 | 114.05 | 66.97 | |
| Net Cash Used In Investing Activities | -77.73 | -109.59 | -12.97 | -92.28 | -61.62 | |
| Net Cash Used From Financing Activities | -26.71 | -20.76 | -26.05 | -12.62 | -11.67 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -7.23 | -4.43 | 4.79 | 9.14 | -6.33 | |
| Cash And Cash Equivalents Begin of Year | 14.17 | 18.60 | 13.82 | 4.67 | 11.00 | |
| Cash And Cash Equivalents End Of Year | 6.95 | 14.17 | 18.60 | 13.82 | 4.67 |
11.03.2026
10.03.2026
09.03.2026
04.03.2026
Natco Pharma shares rise 2% on Pomalidomide capsules launch in US
20.02.2026
Bliss GVS Consolidated December 2025 Net Sales at Rs 218.25 crore, up 3.72% Y-o-Y
19.02.2026
Bliss GVS Standalone December 2025 Net Sales at Rs 164.68 crore, down 8.3% Y-o-Y
07.11.2025
Bliss GVS Consolidated September 2025 Net Sales at Rs 244.40 crore, up 12.27% Y-o-Y
30.07.2025
Bliss GVS Consolidated June 2025 Net Sales at Rs 207.47 crore, up 12.97% Y-o-Y
20.02.2026
Bliss GVS Consolidated December 2025 Net Sales at Rs 218.25 crore, up 3.72% Y-o-Y
19.02.2026
Bliss GVS Standalone December 2025 Net Sales at Rs 164.68 crore, down 8.3% Y-o-Y
07.11.2025
Bliss GVS Consolidated September 2025 Net Sales at Rs 244.40 crore, up 12.27% Y-o-Y
30.07.2025
Bliss GVS Consolidated June 2025 Net Sales at Rs 207.47 crore, up 12.97% Y-o-Y
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities